Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

BOLT
Bolt Biotherapeutics, Inc. Common Stock
stock NASDAQ

At Close
Jul 31, 2026 3:59:30 PM EDT
3.99USD+2.571%(+0.10)20,000
0.00Bid   0.00Ask   0.00Spread
Pre-market
0.00USD-100.000%(-3.89)0
After-hours
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 6, 2022
10:06AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022   Benzinga
09:48AM EST  Morgan Stanley Downgrades Bolt Biotherapeutics to Equal-Weight, Lowers Price Target to $11   Benzinga
08:03AM EST  Bolt Biotherapeutics Doses First Patient With BDC-1001 In Combination With OPDIVO In Ongoing Phase 1/2 Clinical Trial For Treatment Of HER2-Expressing Solid Tumors   Benzinga
08:00AM EST  Bolt Biotherapeutics Doses First Patient with BDC-1001 in   GlobeNewswire Inc
Dec 23, 2021
09:33AM EST  IIROC Trade Resumption - BOLT   PR Newswire
Dec 22, 2021
07:56AM EST  IIROC Trading Halt - BOLT   PR Newswire
Dec 16, 2021
08:00AM EST  Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the appointment of Nicole Onetto, M.D., to its Board of Directors effective Dec. 14, 2021.   GlobeNewswire Inc
Dec 6, 2021
02:31PM EST  Mid-Afternoon Market Update: Dow Jumps 700 Points; Del Taco Restaurants Shares Spike Higher   Benzinga
12:30PM EST  Mid-Day Market Update: Crude Oil Rises 3%; Aeglea BioTherapeutics Shares Plunge   Benzinga
10:03AM EST  Mid-Morning Market Update: Markets Mostly Higher; Science Applications International Posts Upbeat Earnings   Benzinga
06:12AM EST  Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Shows Well-tolerated Profile And Emerging Clinical Activity   RTTNews
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
06:03AM EST  Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating A Safe And Well-tolerated Profile And Emerging Clinical Activity At The ESMO Immuno-Oncology Congress 2021   Benzinga
06:00AM EST  Company to continue monotherapy dose-escalation and evaluate weekly dose regimen   GlobeNewswire Inc
Dec 2, 2021
06:07AM EST  Bolt Biotherapeutics To Present Interim Clinical Data On BDC-1001 Phase 1/2 Clinical Trial At ESMO Immuno-Oncology Congress 2021   Benzinga
06:00AM EST  Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001   GlobeNewswire Inc
Nov 19, 2021
08:00AM EST  Bolt Biotherapeutics Announces Changes to its Board of Directors   GlobeNewswire Inc
Nov 12, 2021
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:18AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:17AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:16AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:15AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:14AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:12AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:00AM EST  Bolt Biotherapeutics Presents New Preclinical Data on Three   GlobeNewswire Inc
Nov 10, 2021
06:30AM EST  SVB Leerink Maintains Outperform on Bolt Biotherapeutics, Lowers Price Target to $33   Benzinga
Nov 9, 2021
04:05AM EST  BDC-1001 Phase 1/2 dose-escalation interim clinical trial update in HER2-expressing solid tumors to be presented at ESMO Immuno-Oncology Congress 2021Strong cash position of $295.5 million expected to fund operations through the end of 2023   GlobeNewswire Inc
Nov 8, 2021
08:00AM EST  Bolt Biotherapeutics to Present at Stifel 2021 Virtual Healthcare   GlobeNewswire Inc
Nov 3, 2021
08:00AM EDT  89bio Announces Appointment of Kathy LaPorte to its Board of Directors   GlobeNewswire Inc
Oct 1, 2021
08:03AM EDT  Bolt Biotherapeutics To Present Updates On Three Pipeline Programs At 2021 Society For Immunotherapy Of Cancer Annual Meeting Nov. 13   Benzinga
08:00AM EDT  Bolt Biotherapeutics to Present Updates on Three Pipeline Programs   GlobeNewswire Inc
Sep 8, 2021
07:30AM EDT  Bolt Biotherapeutics Announces Clinical Collaboration with Bristol   GlobeNewswire Inc
Sep 2, 2021
08:00AM EDT  Bolt Biotherapeutics to Participate in Upcoming September Investor   GlobeNewswire Inc
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
06:10AM EDT  Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates   Benzinga
Aug 26, 2021
04:11PM EDT  Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody ISAC Programs   Benzinga
04:05PM EDT  Bolt Biotherapeutics and Innovent Biologics Announce Collaboration   GlobeNewswire Inc
Aug 16, 2021
06:34AM EDT  SVB Leerink Maintains Outperform on Bolt Biotherapeutics, Raises Price Target to $35   Benzinga
Aug 12, 2021
04:53PM EDT  Bolt Biotherapeutics Q2 Loss From Operations $23.8M vs Loss $11.1M In Same Qtr. Last Year   Benzinga
04:05PM EDT  BDC-1001 Phase 1/2 trial in HER2-expressing solid tumors on track for data update in 2H 2021   GlobeNewswire Inc
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 7, 2021
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jun 30, 2021
07:29AM EDT  The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs   Benzinga
Jun 23, 2021
07:35AM EDT  The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway   Benzinga
Jun 15, 2021
08:07AM EDT  The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda   Benzinga
Jun 8, 2021
09:17AM EDT  The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex   Benzinga
Jun 4, 2021
09:10AM EDT  Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody ISAC BDC-1001 at ASCO 2021   Benzinga
09:00AM EDT  -- Poster showcases positive preliminary data from first 20 patients treated with the HER2-targeting Boltbody ISAC BDC-1001 as of January 29th cutoff date -- Monotherapy dose expansion and anti-PD-1 antibody combination parts of study expected to start in 2H 2021   GlobeNewswire Inc
Jun 3, 2021
08:23AM EDT  The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout   Benzinga
Jun 2, 2021
08:19AM EDT  Genmab, Bolt Biotherapeutics Enter Oncology Research And Development Collaboration   RTTNews
08:14AM EDT  Genmab A/S, Bolt Biotherapeutics Sign Oncology Research And development Collaboration   RTTNews
08:04AM EDT  Genmab And Bolt Biotherapeutics Announce Oncology Research And Development Collaboration; Bolt To Receive $10M Upfront Payment And $15M Equity Investment From Genmab   Benzinga
08:00AM EDT  Genmab and Bolt Biotherapeutics Announce Oncology Research and   GlobeNewswire Inc
May 27, 2021
08:24AM EDT  The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs   Benzinga
May 26, 2021
07:33AM EDT  The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing   Benzinga
May 17, 2021
08:11AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:21AM EDT  SVB Leerink Maintains Outperform on Bolt Biotherapeutics, Lowers Price Target to $33   Benzinga
May 13, 2021
04:19PM EDT  Bolt Biotherapeutics Q1 EPS $(1.14) Up From $(4.16) YoY   Benzinga
04:05PM EDT  Strong cash position of $302.9 million as of March 31, 2021 expected to deliver key value-creating milestones and fund operations into 2023   GlobeNewswire Inc
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
Apr 13, 2021
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
Apr 12, 2021
10:30AM EDT  Bolt Biotherapeutics Saturday Morning Announced Presentation Of Boltbody Platform Mechanism Of Action, Clinical Properties Of Lead ISAC, BDC-1001 At American Association For Cancer Research Conference   Benzinga
Apr 10, 2021
08:30AM EDT  Bolt Biotherapeutics Announces AACR 2021 Presentation of   GlobeNewswire Inc
Apr 8, 2021
07:00AM EDT  Bolt Biotherapeutics to Present at 20th Annual Needham Virtual   GlobeNewswire Inc
Apr 6, 2021
07:41AM EDT  SVB Leerink Maintains Outperform on Bolt Biotherapeutics, Raises Price Target to $37   Benzinga
Mar 31, 2021
04:11PM EDT  Bolt Biotherapeutics Q4 EPS $(14.58) Down From $(4.55) YoY   Benzinga
04:05PM EDT  Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a total of $358 million in recent fundraising   GlobeNewswire Inc
Mar 12, 2021
07:36AM EST  The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs   Benzinga
Mar 11, 2021
08:19AM EST  The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena   Benzinga
Mar 10, 2021
07:26AM EST  The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link   Benzinga
Mar 2, 2021
01:15PM EST  Stifel Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $40   Benzinga
10:02AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2021   Benzinga
09:38AM EST  Guggenheim Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $42   Benzinga
07:55AM EST  Morgan Stanley Initiates Coverage On Bolt Biotherapeutics with Overweight Rating, Announces Price Target of $45   Benzinga
07:07AM EST  SVB Leerink Initiates Coverage On Bolt Biotherapeutics with Outperform Rating, Announces Price Target of $36   Benzinga
Feb 27, 2021
09:04PM EST  The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings   Benzinga
Feb 13, 2021
12:54PM EST  The Past Week's Notable Insider Buys: Biotech IPOs, Curiositystream, Greenbrier And More   Benzinga
Feb 9, 2021
04:05PM EST  Bolt Biotherapeutics Announces Closing of Initial Public Offering   GlobeNewswire Inc
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Feb 5, 2021
10:51AM EST  Bolt Biotherapeutics Shares Open For Trade At $26.10; IPO Priced At $20/Share   Benzinga
10:31AM EST  Bolt Biotherapeutics Shares Will Open For Quote At 10:10 a.m. EST, Expected To Open For Trade After 10:20 a.m. EST; IPO Priced At $20/Share   Benzinga
10:28AM EST  BioLight Life Sciences Shares Indicated $26 On 322K Shares   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC